These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37478179)

  • 1. Mechanisms of HIV-1 integrase resistance to dolutegravir and potent inhibition of drug-resistant variants.
    Li M; Oliveira Passos D; Shan Z; Smith SJ; Sun Q; Biswas A; Choudhuri I; Strutzenberg TS; Haldane A; Deng N; Li Z; Zhao XZ; Briganti L; Kvaratskhelia M; Burke TR; Levy RM; Hughes SH; Craigie R; Lyumkis D
    Sci Adv; 2023 Jul; 9(29):eadg5953. PubMed ID: 37478179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
    Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
    Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.
    Mesplède T; Osman N; Wares M; Quashie PK; Hassounah S; Anstett K; Han Y; Singhroy DN; Wainberg MA
    J Antimicrob Chemother; 2014 Oct; 69(10):2733-40. PubMed ID: 24917583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants.
    Smith SJ; Zhao XZ; Burke TR; Hughes SH
    Retrovirology; 2018 May; 15(1):37. PubMed ID: 29769116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
    Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
    J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Close-up: HIV/SIV intasome structures shed new light on integrase inhibitor binding and viral escape mechanisms.
    Engelman AN; Cherepanov P
    FEBS J; 2021 Jan; 288(2):427-433. PubMed ID: 32506843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants.
    Smith SJ; Zhao XZ; Passos DO; Lyumkis D; Burke TR; Hughes SH
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32601157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
    Hassounah SA; Alikhani A; Oliveira M; Bharaj S; Ibanescu RI; Osman N; Xu HT; Brenner BG; Mesplède T; Wainberg MA
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout.
    Osman N; Mesplède T; Oliveira M; Hassounah S; Wainberg MA; Brenner BG
    AIDS; 2018 Aug; 32(13):1773-1780. PubMed ID: 29894388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study.
    Cheung PK; Shahid A; Dong W; Lepik KJ; Montaner JSG; Brockman MA; Brumme ZL; Brumme CJ
    J Antimicrob Chemother; 2022 Mar; 77(4):979-988. PubMed ID: 35061879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572).
    Hare S; Smith SJ; Métifiot M; Jaxa-Chamiec A; Pommier Y; Hughes SH; Cherepanov P
    Mol Pharmacol; 2011 Oct; 80(4):565-72. PubMed ID: 21719464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase.
    Quashie PK; Mesplède T; Han YS; Veres T; Osman N; Hassounah S; Sloan RD; Xu HT; Wainberg MA
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6223-35. PubMed ID: 24080645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selectivity for strand-transfer over 3'-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site.
    Métifiot M; Johnson BC; Kiselev E; Marler L; Zhao XZ; Burke TR; Marchand C; Hughes SH; Pommier Y
    Nucleic Acids Res; 2016 Aug; 44(14):6896-906. PubMed ID: 27369381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-Naive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1.
    Sayan M; Yildirim FS; Akhan S; Karaoglan I; Akalin H
    Curr HIV Res; 2022 Aug; 20(2):184-192. PubMed ID: 35240975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
    Tsiang M; Jones GS; Goldsmith J; Mulato A; Hansen D; Kan E; Tsai L; Bam RA; Stepan G; Stray KM; Niedziela-Majka A; Yant SR; Yu H; Kukolj G; Cihlar T; Lazerwith SE; White KL; Jin H
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7086-7097. PubMed ID: 27645238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.
    Quashie PK; Mesplède T; Han YS; Oliveira M; Singhroy DN; Fujiwara T; Underwood MR; Wainberg MA
    J Virol; 2012 Mar; 86(5):2696-705. PubMed ID: 22205735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations.
    Mikasi SG; Isaacs D; Chitongo R; Ikomey GM; Jacobs GB; Cloete R
    BMC Infect Dis; 2021 Apr; 21(1):379. PubMed ID: 33892628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
    Santoro MM; Fornabaio C; Malena M; Galli L; Poli A; Menozzi M; Zazzi M; White KL; Castagna A;
    Int J Antimicrob Agents; 2020 Jul; 56(1):106027. PubMed ID: 32450199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
    Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
    mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
    Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ
    J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.